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Abstract 
Effect of Macrophage Activity and Age on Periodontal Disease 
Benjamin James Halpern 
Background: Periodontal disease is an inflammatory disease that increases in prevalence with 
increasing age. The elderly demonstrate an elevated and dysregulated inflammatory response. 
Macrophages act as a key regulator of inflammation. The study aim was to evaluate the extent 
to which age-related changes and chemical inhibition in the macrophage affect periodontal 
disease in a mouse model.  
Methods: Old (24 month) and young (3 month) mice were utilized for this study. Periodontal 
status was examined in mice at baseline. Periodontal disease was induced via Porphyromonas 
gingivalis (P. gingivalis) inoculated ligatures in old and young mice for 7 days. A second cohort 
had disease induced for 7 days, followed by ligature removal, and recovery for 7 additional 
days. Half the mice in each induction or recovery group were treated with Pexidartinib (PLX), 
which inhibits macrophage recruitment. Linear bone loss, alveolar bone volume, and 
macrophage quantification were examined by t test. 
Results: PLX successfully inhibited macrophage numbers in all treatment groups. The young 
periodontal disease group had significantly more vertical bone loss (0.234±0.024mm) compared 
to the young periodontal disease PLX group (0.140±0.023mm)(p≤0.001) and less alveolar bone 
volume (0.460±0.016BV/TV) compared to the young periodontal disease PLX group  
(0.586±0.004BV/TV)(p≤0.001). The old periodontal disease group exhibited no difference in 
vertical bone loss (0.242±0.025mm) compared to the old periodontal disease PLX group 
(0.238±0.032mm)(p=0.825) and significantly less alveolar bone volume (0.536±0.030BV/TV) 
compared to the old periodontal disease PLX group (0.614±0.030BV/TV)(p≤0.01). The young 
recovery control group trended towards less vertical bone loss (0.170±0.020mm) compared to 
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the young recovery + PLX group (0.190±0.011mm)(p=0.055) and had no difference in alveolar 
bone volume (0.557±0.015 BV/TV) compared to the young recovery PLX group (0.545±0.011 
BV/TV)(p=0.131). The old recovery control group exhibited no difference in vertical bone loss 
(0.241±0.019mm) compared to the old recovery + PLX group (0.218±0.035mm)(p=0.187) and 
had significantly less alveolar bone volume (0.567±0.021BV/TV) compared to the old recovery 
PLX group (0.617±0.023BV/TV)(p≤0.01). 
Conclusion: 
PLX prevents periodontal disease induction in old and young groups and improves recovery in 
older age groups. The difference in response during recovery could suggest that there are age 
related changes in the macrophage that affect disease progression.   
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I. Introduction 
Periodontal disease is a chronic inflammatory disease characterized by the destruction of the 
supporting structures of the teeth.1 Periodontal disease is characterized by gingival inflammation 
that leads to loss of alveolar bone and periodontal tissues.2 The etiology of the disease is 
primarily attributed to a dysbiosis between the host response and bacterial biofilm.3,4 Individuals 
with severe and rapidly progressing forms of the disease exhibit an excessive host response 
and currently no treatment exists to modulate this response.5  
Periodontal disease severity and prevalence increases with age. Approximately 46% of US 
adults, representing 64.7 million people, have periodontal disease, with 8.9% having a severe 
form of the disease.6 Of adults 35-49 years of age, 36.6% have periodontal disease, which 
increases to 68% in adults 65 and older.6 Further, with the aging demographic in the US it is 
expected that the incidence of periodontal disease will increase as the population ages.7  
The elderly demonstrate a chronically elevated and dysregulated inflammatory response. The 
term “inflamm-aging” has been used to describe the systemic pro-inflammatory status 
associated with aging that predisposes the elderly population to a wide range of age-associated 
disease and conditions.3,8 Osteoporosis, Alzheimer’s disease, Type II diabetes, atherosclerosis, 
and Parkinson’s disease all become more prevalent with increased age and all have an 
underlying inflammatory component associated with their onset and progression.9–12  It has 
been proposed that inflamm-aging results from a defect in the resolution of inflammation or from 
a chronic unknown mechanism that signals and prolongs the inflammatory response.13 
Experimental gingivitis studies have shown that a similar process happens in the periodontium, 
as older populations develop more gingivitis than younger populations.14 
The immune response during periodontal disease utilizes components of both innate and 
adaptive immunity.3 The early innate immune response is characterized by the presence of 
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neutrophils and macrophages. Both of these cellular inflammatory mediators are implicated in 
the protective and destructive host response.15  
Macrophages act as a key regulator of inflammation, and thus play an important role in 
periodontal disease induction and recovery.16 The role of macrophages during the inflammatory 
response includes initiation of inflammation, activation of lymphocyte-mediated adaptive 
immunity, mediation of alveolar bone resorption, and resolution of inflammation and tissue 
repair.16  Macrophages have both pro-inflammatory (M1) and anti-inflammatory (M2) 
phenotypes.17 M1 macrophages exhibit increased phagocytosis, increased antigen 
presentation, as well as increased production of the pro inflammatory cytokines TNF-𝛼, IL-1β, 
and IL-6.16,18 The M2 macrophage produces the anti-inflammatory cytokine IL-10 as well as 
growth factors required for wound healing: TGFβ, VEGF, PDGF.16,19 The M1 phenotype aids in 
promoting inflammation and killing bacteria, however, the M2 phenotype aids in tissue repair, 
tissue homeostasis and inhibition and resolution of inflammation. An imbalance in the M1/M2 
ratio is common in the pathogenesis of many inflammatory diseases, including periodontal 
disease. 
Age related molecular alterations in macrophages include compromised chemotaxis and 
phagocytosis, production of reactive oxygen species, and increased cytokine production.15 With 
increased age, macrophages exhibit reduced production of reactive oxygen species and 
cytokines, such as IL-6, TNF-α, MIP-1α, MIP-1β, and MIP-2, and increased production of 
receptors involved in inflammation amplification (C5aR, TREM-1) and PGE2 production.15,20 The 
age-related reduction in chemotaxis by macrophages was demonstrated in a murine model and 
may be due to a reduced production of chemokines, such as macrophage inflammatory protein-
1α (MIP-1α), MIP-1β, and MIP-2.15,21 Research on macrophage phagocytosis as a function of 
age, has been inconclusive and conflicting, with studies showing increased, decreased, and 
unaltered phagocytosis with increased age.15,20 In terms of periodontal disease, macrophages 
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from both young and old mice exhibit similar capacity to phagocytize a major periodontal 
pathogen, P. gingivalis.15,22 Reduced production for some inflammatory mediators, such as IL-6, 
TNF-α, IL-12, IFN-γ, occurs with increasing age. However, some mediators may increase with 
age such as PGE2.15,20,23,24  IL-12 stimulates cell mediated immunity. The ability of PGE2 to 
inhibit production of IL-12 may decrease older individuals ability to clear infections.15,24 PGE2 is 
heavily involved with periodontal destruction.15,25 The elevated levels of PGE2 in old age could 
be one of the reasons for the increased severity of periodontal disease in the elderly 
population.15 In vitro findings have shown that age does not affect macrophage ability to kill P. 
gingivalis, however, in vivo studies have shown impaired killing.15 This suggests that age-
dependent changes in the local environment may inhibit macrophage ability to kill periodontal 
pathogens.15 
The dichotomous nature of the macrophage make it a potentially useful target for creating novel 
treatments for periodontal disease. Inhibition of macrophage recruitment has been 
accomplished with the use of Pexidartinib (PLX) (Plexxikon, Berkeley, CA). PLX is a kinase 
inhibitor that antagonizes macrophage colony-stimulating factor-1 (CSF-1) receptor, which is a 
key regulator of monocyte differentiation and activation.26  PLX has been used previously in 
cancer treatment. It successfully inhibited tumor-associated macrophages and caused a delay 
in melanoma outgrowth.27 PLX also significantly decreased macrophage recruitment into the 
fracture callus, which resulted in improved healing of tibial shaft fractures in elderly mice.28 The 
ability of PLX to aid in the recovery of long bones suggests that it may be a useful 
pharmacologic agent that could assist in the recovery of alveolar bone lost due to periodontal 
disease. 
Mouse models of periodontal disease have been used to study disease mechanisms and in the 
research of new therapeutic approaches.29–31 Mouse models are useful because the disease 
process and initiation of inflammation can be controlled through placement of a ligature. The 
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disease process and the resulting alveolar bone loss can be accomplished in a relatively short 
time; from three to ten days.32 Removal of the ligature allows for the study of the resolution of 
inflammation and the recovery process. 
The purpose of this study was to examine the extent to which age-related changes to the 
macrophage affect the pathogenesis of periodontal disease. Currently, it is known that 
macrophages play a role in the immune response to periodontal pathogens and the concurrent 
tissue breakdown in the periodontium. However, the specific role of the macrophage in 
periodontal disease in the context of aging is not well known, and therefore merits further 
investigation. This study utilized an aged mouse model of periodontal disease and 
pharmacological inhibition of macrophage activity to better understand the biology of aging in 
this context and to provide insight into the treatment of periodontal disease. 
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II. Materials and Methods 
Experimental model: All procedures were approved by the UCSF Institutional Animal Care and 
Use Committee. Old (24-month) and young (3-month) male C57BL/6 mice were utilized in 10 
treatment groups with 4 to 7 mice in each group (Table 1). A power analysis was used to 
calculate the sample size to detect a change in alveolar bone height of 0.25mm (α=0.05, 
β=0.80). These values on mean amount of bone loss to be expected in a mouse model of 
experimental periodontitis were derived from the literature. An initial pilot experiment was 
carried out to ensure significance was attainable with the proposed sample size.  
Periodontal disease induction was accomplished by tying a 6-0 nylon suture inoculated with 
Porphyromonas gingivalis (ATCC 33277) around the second maxillary molars. The suture or 
ligature was placed bilaterally and in a subgingival position (Figure 1.1). Old and young controls 
did not receive a ligature, and therefore did not exhibit experimental periodontitis. These 
controls were utilized for analysis at baseline. Ligatures were placed for 7 days for induction of 
periodontal disease in old and young mice. A second cohort had disease induced for 7 days, 
then the sutures were removed and the mice were allowed to recover for 7 additional days. Half 
of the mice in each induction or recovery group were treated with PLX, which was placed in the 
chow and given ad libitum (Table 1). At the end of the induction of recovery period, mice were 
euthanized via CO2 overdose and cervical dislocation. The maxilla were retrieved immediately 
and prepared for evaluation of bone loss measurements or immunohistochemistry. To prepare 
for bone loss measurements, the maxilla were defleshed, soaked in 30% hydrogen peroxide 
overnight, then rinsed and stored in 70% ethanol at 4°C until subsequent imaging and analysis. 
Macrophage Inhibition: Inhibition of macrophage recruitment was accomplished by 
administration of PLX. PLX is a small molecule inhibitor of the macrophage colony stimulating 
factor 1 (MCSF-1) receptor. Antagonizing the MCSF-1 receptor prevents activation and 
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subsequent differentiation of monocytes into macrophages. PLX was delivered via mouse chow 
ad libitum at an average dose of 40mg/kg/day. To evaluate the effect of macrophage activity 
during induction of periodontitis and during recovery (after ligature was removed), PLX was 
administered from days 0-7 or days 7-14 respectively. Non-treated groups received the control 
chow provided by the drug manufacturer.  
Analysis: 
Vertical Bone loss: After tissue preparation the maxillae were stained with 1% methylene blue 
for 5 minutes prior to obtaining measurements. Magnified images of the maxillae were taken 
using a dissecting microscope, and Image J (NIH at https://imagej.nih.gov/ij/) was used to 
measure the bone loss. A ruler was placed in the field of view for calibration. Bone loss was 
measured from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) at 6 sites 
per tooth. Sites included in the bone loss analysis in both the experimental and control groups 
were those limited to the areas directly in contact with the ligature. Sites included were the distal 
buccal of the first molar, distal palatal of the first molar, all 6 sites on the second molar, and the 
mesial buccal and mesial palatal of the third molar (Figure 1.2). The sites that were excluded 
were those not in contact with the ligature. Sites were further excluded if there was damage to 
the tooth or surrounding structures or avulsion of the tooth during preparation. 
Alveolar Bone Volume: Micro CT was used to measure changes in bone volume in the area of 
induced periodontal disease. The 3-dimensional area of interest spanned from the CEJ to the 
apex of the teeth, from the buccal and lingual walls of the maxillary alveolar bone, and from the 
mid-point of the 1st molar to the mid-point of the 3rd molar. The total volume of the area was 
measured, and the bone volume in the area was measured. This is expressed as the bone 
volume divided by the total volume (BV/TV) (Figure 1.3).   
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Macrophage Quantification: Immunohistochemical analysis was used to quantify 
macrophages in the periodontal tissues. The maxillae were fixed in 4% paraformaldehyde for 
24h, then decalcified with 19% ethylenediaminetetraacetic acid (pH 8) for 28 days. The 
decalcified specimens were dehydrated and embedded in paraffin. The tissue blocks were cut 
into sections (8 micrometers) in a mesiodistal direction. Sections were incubated with a purified 
rat anti-mouse F480 antibody (BD Biosciences) overnight at 1:200 dilution, followed by 1:500 
dilutions in HRP conjugated goat anti-mouse IgG (H+L) secondary antibody against the primary 
antibody for 1 hour. The sections were then incubated with a 3,3’-diaminobenzidine (DAB) 
substrate and observed under microscopy. Photographs were taken at 200x, and 3 regions of 
interest per sample that were adjacent to the tooth, including the epithelium, connective tissue 
and bone in the coronal 1/3 of the root were analyzed at 400x (Fig 1.4). The region of interest 
had a field of view (FOV) of 0.23mm². F480+ macrophages were quantified using Image J 
imaging software. The 3 regions were averaged per sample for each mouse.  
Statistical Methods: For vertical bone loss measurements, the mouse mean value was the unit 
used for statistical analysis.33 For the volumetric analysis, the BV/TV was calculated per sample. 
Bone loss and macrophage quantification measurements were first analyzed via ANOVA for 
significant differences, and between group differences were analyzed using a two tailed T-test. 
Significance was determined at p<0.05.  
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III. Results 
Young Control vs Old Control 
The young control group (n=5) had significantly less vertical bone loss (0.095 ± 0.015mm) 
compared to the old control group (n=4) (0.192 ± 0.007mm) (p ≤ 0.001) (Figure 2.1, 2.2). No 
differences in F 480+ macrophage quantity were found between the young control group (n=6) 
(11.7 ± 7.3 cells/FOV) compared to the old control group (n=7) (9.0 ± 6.6 cells/FOV) (p = 0.50) 
(Figure 2.3, 2.4). 
Young Control vs Young Periodontal Disease  
The young periodontal disease group (n=5) had significantly more vertical bone loss (0.234 ± 
0.024mm) compared to the young control group (n=5) (0.095 ± 0.015mm) (p ≤ 0.001) (Figure 
3.1, 3.2). The young periodontal disease group (n=5) had significantly more F480+ 
macrophages (50.33 ± 7.4 cells/FOV) compared to the young control group (n=6) (11.7 ± 7.3 
cells/FOV) (p ≤ 0.001) (Figure 3.3, 3.4). 
Old Control vs Old Periodontal Disease 
The old periodontal disease group (n=6) had significantly more vertical bone loss (0.242 ± 
0.025mm) compared to the old control group (n=4) (0.192 ± 0.007) (p ≤ 0.01) (Figure 4.1, 4.2). 
The old periodontal disease group (n=6) had significantly more F480+ macrophages (74.2 ± 
27.7 cells/FOV) compared to the old control group (n=7) (9 ± 6.6 cells/FOV) (p ≤ 0.001) (Figure 
4.3, 4.4). 
Young Periodontal Disease vs Young Periodontal Disease + PLX 
The young periodontal disease group (n=5) had significantly more vertical bone loss (0.234 ± 
0.024mm) compared to the young periodontal disease + PLX group (n=5) (0.140 ± 0.023mm) (p 
≤ 0.001) (Fig 5.1, 5.2). The young periodontal disease group (n=5) had significantly less alveolar 
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bone volume (0.460 ± 0.016 BV/TV) compared to the young periodontal disease + PLX group 
(n=5) (0.586 ± 0.004 BV/TV) (p ≤ 0.001) (Fig 5.3). The young periodontal disease group (n=5) 
had significantly more F480+ macrophages (50.3 ± 7.4 cells/FOV) compared to the young 
periodontal disease + PLX group (n=5) (11.7 ± 8.4) (p ≤ 0.001) (Figure 5.4, 5.5). 
Old Periodontal Disease vs Old Periodontal Disease + PLX 
The old periodontal disease group (n=6) had no difference of vertical bone loss (0.242 ± 
0.025mm) compared to the old periodontal disease + PLX group (n=6) (0.238 ± 0.032mm) (p = 
0.825) (Fig 6.1, 6.2). The old periodontal disease group (n=5) had significantly less alveolar 
bone volume (0.536 ± 0.030 BV/TV) compared to the old periodontal disease + PLX group (n=5) 
(0.614 ± 0.030) (p ≤ 0.01) (Fig 6.3). The old periodontal disease group (n=6) had significantly 
more F480+ macrophages (74.2 ± 27.7 cells/FOV) compared to the old periodontal disease + 
PLX group (n=6) (24.4 ± 13.0 cells/FOV) (p ≤ 0.01) (Fig 6.4, 6.5). 
Young Recovery Control vs Young Recovery + PLX 
The young recovery control group (n=6) trended towards less vertical bone loss (0.170 ± 
0.020mm) compared to the young recovery + PLX group (n=6) (0.190 ± 0.011mm) (p=0.055) 
(Fig 7.1, 7.2) The young recovery control (n=6) had no difference in alveolar bone volume 
(0.557 ± 0.015 BV/TV) compared to the young recovery + PLX group (n=6) (0.545 ± 0.011 
BV/TV) (p = 0.131) (Fig 7.3). The young recovery control group (n=6) had significantly more 
F480+ macrophages (54.6 ± 9.6 cells/FOV) compared to the young recovery + PLX group (n=6) 
(5.4 ±4.7 cells/FOV) (p ≤ 0.001) (Fig 7.4, 7.5). 
Old Recovery Control vs Old Recovery + PLX 
The old recovery control group (n=6) had no difference in vertical bone loss (0.241 ± 0.019mm) 
compared to the old recovery + PLX (n=7) (0.218 ± 0.035mm) (p = 0.187) (Fig 8.1, 8.2). The old 
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recovery control (n=6) had significantly less alveolar bone volume (0.567 ± 0.021 BV/TV) 
compared to the old recovery + PLX group (n=7) (0.617 ± 0.023 BV/TV) (p ≤ 0.01) (Fig 8.3). The 
old recovery control (n=6) had significantly more F480+ macrophages (47.8 ± 18.3 cells/FOV) 
compared to the old recovery + PLX group (n=7) (5.0 ± 2.3 cells/FOV) (p ≤ 0.001) (Fig 8.4, 8.5). 
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IV. Discussion 
The old control group had significantly more vertical bone loss than the young control group 
(Figure 2.1). This agrees with previous studies that older mice demonstrate an aged periodontal 
disease phenotype that represents a genuinely chronic model to study the mechanisms of 
periodontal destruction.34 In the study by Liang, old mice displayed significantly (p<0.05) 
increased bone loss, elevated proinflammatory cytokines (IL-1β, tumor necrosis factor α, IL-
17A) as well as increased innate immune receptors involved in inflammation (Toll-like receptor 
2, CD14, CD11b, CD18, complement C5a receptor). 34 The fact that mice display a chronic 
disease process similar to humans provides validity to the use of a mouse model to develop 
novel therapeutic approaches for the treatment of periodontitis. 
There was no significant difference in the number of macrophages between the old and young 
control groups (Figure 2.4). In the control groups there was a large standard deviation of the 
macrophage quantification. This may be explained by the “Random Burst” or “Asynchronous 
Multiple Burst” model of periodontal disease progression.35,36 Some areas might have been 
undergoing a burst of disease activity and thus had more macrophages present in their tissues.  
This shows that in the absence of disease, the baseline quantity of macrophages in the 
periodontal tissues is independent of age. 
The ligature induced model was useful for inducing periodontal disease in both young and old 
mice. Both young and old periodontal disease groups had significantly more vertical bone loss 
and less alveolar bone volume compared to their respective controls (Figure 3.1, 4.1). This data 
agrees with previous studies that have induced periodontal disease in mice.32 The linear bone 
measurements attained in this study are similar to other ligature induced models. In the study by 
Li et al, young mice had approximately 0.1mm CEJ-ABC measurement at baseline which 
increased to approximately 0.2mm after 7 days of induction with the ligature.32 In addition to 
more bone loss, both disease groups also had significantly increased numbers of macrophages 
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in their periodontal tissues compared to their controls (Figure 3.3, 4.3). This shows that an 
increased number of macrophages in the periodontal diseased tissues is independent of age.  
Macrophage infiltration of the periodontal tissues was inhibited with the use of PLX. The ligature 
induced periodontal disease model resulted in successful recruitment of macrophages into the 
periodontium. During the induction of disease both the young periodontal disease and old 
periodontal disease groups had significantly more macrophages present in their tissues than 
their respective controls tissues (Figure 3.3, 4.3). PLX treatment was successful in decreasing 
macrophage recruitment in all treated groups. During the induction of disease in both young and 
old mice, there were significantly less macrophages present in both the young and old 
periodontal disease + PLX groups compared to the non-PLX groups (Figure 5.3, 6.3). Similarly, 
during the recovery period, there were significantly less macrophages present in the PLX 
treated Old and Young recovery groups compared to the non-treated recovery groups (Figure 
7.3, 8.3). The inhibition of macrophage recruitment is similar to what has been demonstrated in 
other studies that have shown PLX inhibiting macrophage recruitment in tumors as well during 
fracture healing.27,28 By effectively inhibiting macrophage recruitment in young and old mice, the 
extent to which age-related changes in the macrophage affect the pathogenesis of periodontal 
disease can be studied. 
During the induction of disease, the young group treated with PLX had significantly less vertical 
bone loss and more bone volume compared to its respective control (Figure 5.1, 5.3). The old 
group treated with PLX did not have a significant difference in vertical bone loss but did have 
significantly more alveolar bone volume compared to its respective control (Figure 6.1, 6.3). 
This shows that the macrophage is involved with periodontal destruction and inhibiting its 
contribution to the disease process can slow the progression of disease. 
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During recovery of disease, the young and old PLX groups did not have significantly different 
vertical bone levels compared to their respective controls (Figure 5.1, 6.1). The old recovery 
PLX had significantly more alveolar bone volume compared it the respective control (Figure 
8.3). The young recovery PLX group did not have any difference with its control (Figure 7.3). 
This suggests that inhibiting macrophages in old may have some benefit to preserving alveolar 
bone during the recovery of disease. This is promising, as periodontal disease predominately 
effects older age groups, and this may be a novel therapy that could aid in treating periodontal 
disease.  
In terms of periodontal disease, the strongest effects were seen in the young perio disease 
groups where PLX decreased linear bone loss and increased bone volume. This could lead the 
way to novel treatment for stage III, grade C, molar incisor pattern periodontitis which is most 
commonly seen in younger age groups. There is a genetic component to this type of periodontal 
disease, so at risk individuals could be identified by family history and given the medication 
prophylactically in their youth when they are most susceptible to prevent the rapid bone loss 
seen in these individuals. 
The increased bone volume seen in the Old Recovery + PLX group compared to the old 
recovery group is most applicable to treatment of periodontal disease. Typically, the disease is 
identified in the elderly population and then treatment is performed. The fact that PLX aided in 
the recovery indicates that it may have use as an adjunct to traditional periodontal treatments. 
PLX administration could be combined with traditional periodontal therapies such as scaling and 
root planning or periodontal flap surgery with or without regeneration to aid in recovery.  
More research on the long term effects of systemic PLX administration are needed before its 
widespread use is adopted. In terms of periodontal disease, a locally delivered method would be 
preferable to prevent unwanted systemic effects. However, PLX works by blocking CSF-1 on 
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monocytes in the blood and preventing monocyte differentiation into macrophages. In its current 
form, a locally delivered method would likely not achieve the desired results. As further research 
is conducted into macrophage signaling and differentiation, it may be possible to create 
subclasses of the medication that could be made to only affect recruitment into the periodontal 
tissues. 
Age related changes to the macrophage response can be further studied by looking at local pro-
inflammatory macrophage markers to explain the difference in response between age groups. 
Analyzing cytokines such as IL-6, IL-12 TNF-α, MIP-1α, MIP-1β, MIP-2, C5aR, TREM-1, PGE2 
may helper further elucidate differences between old and young macrophages and the 
mechanisms in which inhibiting macrophages has shown to have a beneficial effect on 
periodontal disease.  
Conclusion 
These data show that modulating the macrophage response has beneficial effects during 
induction and recovery of periodontal disease. This is a promising area of novel treatment for 
periodontal disease. Currently, there are a limited number of treatments for periodontal disease 
that modulate the host response. Novel treatments for periodontal disease, such as host 
response modulation are needed as the disease model of periodontitis has moved away from a 
plaque specific hypothesis to a broader dysbiosis between the host response and bacteria. New 
treatments are needed to address the changing disease progression models. A limitation of the 
current treatment modality is that it affects macrophages systemically, which may have 
detrimental effects in other areas of the body. In order for this treatment to become more 
acceptable and to justify its long term use in humans, a greater understanding of its systemic 
effects and the drug half-life are needed. 
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